IP Verse

Degarelix Drug Product

Patent No. EP4512389 (titled "Degarelix Drug Product") was filed by Ferring on May 31, 2013. The application was issued on Feb 4, 2026.

Patent Summary

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_CFI_0001470/2026Apr 30, 2026Ferring, Ferring CenterInfringement

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ACCORD HEALTHCARE SLUJun 1, 2026BRAND MURRAY FULLER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4512389

FERRING
Application Number
EP25151066A
Filing Date
May 31, 2013
Status
Granted And Under Opposition
Jan 1, 2026
Publication Date
Feb 4, 2026
External Links
Slate, Register , Google Patents